NLRP3
BGE-102: oral CNS-penetrant NLRP3 inhibitor
Lead indication: obesity
NLRP3 is a critical component of the inflammasome. Chronic inflammasome activation results in inflammation that drives metabolic and neuroinflammatory diseases.
Our lead program, BGE-102, is an oral, potent, and highly brain penetrant NLRP3 inhibitor with a novel structure and binding site. In a preclinical obesity model, BGE-102 resulted in dose-dependent weight loss as monotherapy and more than doubled weight loss when combined with an incretin.
We anticipate Phase 1 SAD data by 2025 year end.
(CNS penetrant)
(CNS penetrant)
We have discovered structurally and mechanistically novel inhibitors that bind in a distinct region of NLRP3
Peripheral inflammation and neuroinflammation are key drivers of obesity.
BGE-102 has the potential to address both
Peripheral and neuroinflammation are key
drivers of obesity. BGE-102 has the potential to address both
Peripheral and neuroinflammation
are key drivers of obesity. BGE-102
has the potential to address both
Peripheral inflammation and neuroinflammation are key drivers of obesity.
BGE-102 has the potential to address both
Peripheral and neuroinflammation are key
drivers of obesity. BGE-102 has the potential to address both
Peripheral and neuroinflammation
are key drivers of obesity. BGE-102
has the potential to address both
